Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / B2M

B2M

Basics

Aliases:
This biomarker is also known as:
  • beta-2-microglobulin,
  • CDABP0092,
  • HDCMA22P,

View in BioMuta

Description…

B2M, a secreted protein belonging to the beta-2-microglobulin family, is a component of the class I major histocompatibility complex (MHC) on the surface of nearly all nucleated cells and involved in the presentation of peptide antigens to the immune system. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia. B2M is detected in serum and urine.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

B2M has been shown to be the target molecule of an antibody pool against SKOV3 ovarian cancer cells. Studies have also indicated that specific antibody of B2M can inhibit the growth of SKOV3. In addition, overexpression of B2M promotes the growth of SKOV3 cells in vitro.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. B2M alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html